Loading
Whether the leukaemia's antibody gene has been 'edited' by the immune system. Unmutated means faster-growing CLL and a bigger benefit from targeted drugs over chemotherapy.
IGHV genes with <2% deviation from germline are 'unmutated' (~40-50% of CLL) and predict shorter time to treatment and poor response to chemoimmunotherapy (FCR). BTK inhibitors and venetoclax combinations largely erase the difference for progression, and IGHV status is a stratification factor in every modern CLL trial (CLL13, AMPLIFY). Mutated-IGHV patients still achieve the longest remissions after fixed-duration therapy.
Showing the technology this term belongs to: Comprehensive genomic profiling.
Shares CLL13 / GAIA, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares CLL-IPI (chronic lymphocytic leukaemia prognostic index), AMPLIFY, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Chronic lymphocytic leukaemia, first treatment.
Shares CLL13 / GAIA, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares CLL13 / GAIA, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Chronic lymphocytic leukaemia.
Shares AMPLIFY, CLL13 / GAIA, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares MRD-guided treatment duration in CLL, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares MRD-guided treatment duration in CLL, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.